An experimental drug, daraxonrasib, is offering new hope for patients with advanced pancreatic cancer, a disease known for its high mortality rate. This development was reported at the American Society for Clinical Oncology meeting in Chicago, where researchers shared promising results from a recent study.
Breakthrough in Treatment
The study, involving 500 patients, revealed that those taking daraxonrasib lived a median of 13.2 months, nearly double the survival time of those receiving traditional chemotherapy. This drug targets a mutated protein responsible for tumor growth in over 90% of pancreatic cancer cases, a target that has been challenging to address until now.
Dr. Zev Wainberg of UCLA, who co-led the study, emphasized the significance of these findings, noting that while the drug is not a cure, it represents a substantial advancement in treatment options. The drug’s ability to extend survival with fewer severe side effects marks a notable improvement over existing therapies.
Patient Impact
Patients on daraxonrasib reported less pain and a better quality of life, with many continuing treatment beyond the study period. Dr. Rachna Shroff from the University of Arizona Cancer Center expressed optimism, highlighting the drug’s meaningful benefits for patients.
Dr. Brian Wolpin of the Dana-Farber Cancer Institute suggested that daraxonrasib could become a new standard of care for metastatic pancreatic cancer, with potential applications earlier in the disease’s progression. Researchers are also exploring its use in combination with surgery to improve outcomes.
Future Prospects
The drug, funded by Revolution Medicines, is under expedited review by the FDA, with expanded access available for eligible patients. This development has garnered attention, including from former U.S. Sen. Ben Sasse, who shared his positive experience with the drug on national television.
Pancreatic cancer remains one of the deadliest forms of cancer, with the American Cancer Society estimating over 52,000 deaths in the U.S. this year alone. The introduction of daraxonrasib offers a glimmer of hope in the fight against this challenging disease, with ongoing research into other experimental drugs and treatment approaches.
Original reporting: 40/29 / KHBS (NW Arkansas) — read the source article.
